Modified apolipoprotein (apo) A-I by artificial sweetener causes severe premature cellular senescence and atherosclerosis with impairment of functional and structural properties of apoA-I in lipid-free and lipid-bound state

Molecules and Cells

Volumn 31, Issue 5, 2011, Pages 461-470

  Jang, Wookju ^a   Jeoung, Nam Ho ^b   Cho, Kyung Hyun ^a  

^a Yeungnam University   (South Korea)

^b Catholic University of Daegu   (South Korea)

Author keywords

Apolipoprotein A I; Artificial sweetener; Atherosclerosis; High density lipoprotein; Senescence

Indexed keywords

ACESULFAME; APOLIPOPROTEIN A1; ASPARTAME; HIGH DENSITY LIPOPROTEIN; PHOSPHOLIPID; PHOSPHOLIPID BINDING PROTEIN; SACCHARIN;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL AGING; HUMAN; HUMAN CELL; MACROPHAGE; PHAGOCYTOSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN STRUCTURE; SKIN CELL;

APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CELL AGING; CELL LINE; CELLS, CULTURED; FIBROBLASTS; FRUCTOSE; HUMANS; LIPOPROTEINS, HDL; MACROPHAGES; SWEETENING AGENTS;

EID: 79960699072     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.1007/s10059-011-1009-3     Document Type: Article

References (40)

1. Benzie, I.F., and Strain, J.J. (1996). The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay. Anal. Biochem. 239, 70-76.
2. Brewer, H.B. Jr., Ronan, R., Meng, M., and Bishop, C. (1986). Isolation and characterization of apolipoprotein A-I, A-II, and A-IV. Methods Enzymol. 128, 223-246. (Pubitemid 16100894)
3. Chen, Y.H., Yang, J.T., and Martinez, H.M. (1972). Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. Biochemistry 11, 4120-4131.
4. Cho, K.H. (2009a). Biomedicinal implications of high-density lipoprotein: its composition, structure, functions, and clinical applications. BMB Rep. 42, 393-400.
5. Cho, K.H. (2009b). Synthesis of reconstituted high-density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL. Mol. Cells 27, 291-297.
6. Cho, K.H., Park, S.H., Han, J.M., Kim, H.C., Choi, Y.K., and Choi, I. (2006). ApoA-I mutants V156K and R173C promote anti-inflammatory function and antioxidant activities. Eur. J. Clin. Invest. 36, 875-882. (Pubitemid 44707087)
7. Cho, K.H., Park, S.H., Han, J.M., Kim, H.C., Chung, Y.J., Choi, I., and Kim, J.R. (2007). A point mutant of apolipoprotein A-I, V156K, exhibited potent anti-oxidant and anti-atherosclerotic activity in hypercholesterolemic C57BL/6 mice. Exp. Mol. Med. 39, 160-169. (Pubitemid 46683401)
8. DeGarmo, O., Ashworth, G.W., Eaker, C.M., and Munch, R.H. (1952) Hydrolytic stability of saccharin. J. Am. Pharm. Assoc. Am. Pharm. Assoc. 41, 17-18.
9. Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, M., Rubelj, I., Pereira-Smith, O., et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92, 9363-9367.
10. Eberini, I., Calabresi, L., Wait, R., Tedeschi, G., Pirillo, A., Puglisi, L., Sirtori, C.R., and Gianazza, E. (2002). Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N-and C-termini. Biochem. J. 362, 627-634. (Pubitemid 34242313)
11. Eberini, I., Gianazza, E., Breghi, L., Klugmann, S., Calabresi, L., Gomaraschi, M., Mombelli, G., Brusoni, B., Wait, R., and Sirtori, C.R. (2007). Apolipoprotein A-I breakdown is induced by thrombolysis in coronary patients. Ann. Med. 39, 306-311. (Pubitemid 46897663)
12. Esterbauer, H., Striegl, G., Puhl, H., and Rotheneder, M. (1989). Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic. Res. Commun. 6, 67-75. (Pubitemid 19109796)
13. Feng, H., and Li, X.A. (2009). Dysfunctional high-density lipoprotein. Curr. Opin. Endocrinol. Diabetes Obes. 16, 156-162.
14. Fraenkal-Conrat, H. (1957). Methods for investigating essential groups for enzyme activity. Meth. Enzymol. 4, 247-269.
15. Jaleel, A., Henderson, G.C., Madden, B.J., Klaus, K.A., Morse, D.M., Gopala, S., and Nair, K.S. (2010). Identification of de novo synthesized and relatively older proteins: accelerated oxidative damage to de novo synthesized apolipoprotein A-1 in type 1 diabetes. Diabetes 59, 2366-2374.
16. Ji, Y., and Jonas, A. (1995). Properties of an N-terminal proteolytic fragment of apolipoprotein AI in solution and in reconstituted high density lipoproteins. J. Biol. Chem. 270, 11290-11297.
17. Liz, M.A., Gomes, C.M., Saraiva, M.J., and Sousa, M.M. (2007). ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J. Lipid Res. 48, 2385-2395. (Pubitemid 350058750)
18. Markwell, M.A., Haas, S.M., Bieber, L.L., and Tolbert, N.E. (1978). A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87, 206-210. (Pubitemid 9050428)
19. McPherson, J.D., Shilton, B.H., and Walton, D.J. (1988). Role of fructose in glycation and cross-linking of proteins. Biochemistry 27, 1901-1907.
20. Mukherjee, A., and Chakrabarti, J. (1997). In vivo cytogenetic studies on mice exposed to acesulfame-K-a non-nutritive sweetener. Food Chem. Toxicol. 35, 1177-1179. (Pubitemid 28021666)
21. Nofer, J.R., Walter, M., and Assmann, G. (2005). Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence. Expert Rev. Cardiovasc. Ther. 3, 1071-1086. (Pubitemid 41748374)
22. Odegaard, A.O., Koh, W.P., Arakawa, K., Yu, M.C., and Pereira, M.A. (2010). Soft drink and juice consumption and risk of physician-diagnosed incident type 2 diabetes: the Singapore ChineseHealth Study. Am. J. Epidemiol. 171, 701-708.
23. Oliveira-da-Silva, A., Vieira, F.B., Cristina-Rodrigues, F., Filgueiras, C.C., Manh̃es, A.C., and Abreu-Villaça, Y. (2009). Increased apoptosis and reduced neuronal and glial densities in the hippocampus due to nicotine and ethanol exposure in adolescent mice. Int. J. Dev. Neurosci. 27, 539-548.
24. Olney, J.W., Farber, N.B., Spitznagel, E., and Robins, L.N. (1996). Increasing brain tumor rates: is there a link to aspartame? J. Neuropathol. Exp. Neurol. 55, 1115-1123. (Pubitemid 26372788)
25. Park, K.H., and Cho, K.H. (2011) High-density lipoproteins (HDL) from elderly and reconstituted HDL containing glycated apolipoproteins A-I share pro-atherosclerotic and pro-senescent properties with increased cholesterol influx. J. Gerontol. A. Biol. Sci. Med. Sci. 66, 511-520.
26. Park, K.H., Jang, W., Kim, K.Y., Kim, J.R., and Cho, K.H. (2010a). Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. Biochem. Biophys. Res. Commun. 392, 295-300.
27. Park, K.H., Shin, D.G., Kim, J.R., and Cho, K.H. (2010b). Senescence-related truncation and multimerization of apolipoprotein AI in high-density lipoprotein with an elevated level of advanced glycated end products and cholesteryl ester transfer activity. J. Gerontol. A Biol. Sci. Med. Sci. 65, 600-610.
28. Park, K.H., Yun, C.O., Kwon, O.J., Kim, C.H., Kim, J.R., and Cho, K.H. (2010c). Enhanced delivery of an adenovirus using proteoliposomes containing WT or V156K apolipoproteinA-I and dimyristoylphosphatidylcholine. Hum. Gene Ther. 21, 579-587.
29. Pownall, H.J., Massey, J.B., Kusserow, S.K., and Gotto, A.M. Jr. (1978). Kinetics of lipid-protein interactions: interaction of apolipoprotein A-I from human plasma high density lipoproteins with phosphatidylcholines. Biochemistry 17, 1183-1188. (Pubitemid 8330713)
30. Reuber, M.D. (1978). Carcinogenicity of saccharin. Environ. Health Perspect 25, 173-200.
31. Rye, K.A., and Barter, P.J. (2008). Antiinflammatory actions of HDL: a new insight. Arterioscler. Thromb. Vasc. Biol. 28, 1890-1891.
32. Sasaki, Y.F., Kawaguchi, S., Kamaya, A., Ohshita, M., Kabasawa, K., Iwama, K., Taniguchi, K., and Tsuda, S. (2002) The comet assay with 8 mouse organs: results with 39 currently used food additives. Mutat. Res. 519, 103-119. (Pubitemid 34874991)
33. Scarmeas, N. (2007). Invited commentary: lipoproteins and dementia - Is it the apolipoprotein A-I? Am. J. Epidemiol. 165, 993-997. (Pubitemid 46598839)
34. Seo, S.J., Park, K.H., and Cho, K.H. (2008). Apolipophorin III from H yphantria cunea shows different anti-oxidant ability against LDL oxidation in the lipid-free and lipid-bound state. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 151, 433-439.
35. Staros, J.V. (1982). N-hydroxysulfosuccinimide active esters: bis(Nhydroxy-sulfosuccinimide) esters of two dicarboxylic acids are hydrophilic, membrane-impermeant, protein cross-linkers. Biochemistry 21, 3950-3955.
36. Upmeier, E., Lavonius, S., Lehtonen, A., Viitanen, M., Isoaho, H., and Arve, S. (2009). Serum lipids and their association with mortality in the elderly: a prospective cohort study. Aging Clin. Exp. Res. 21, 424-430.
37. Van den Eeden, S.K., Koepsell, T.D., Longstreth, W.T. Jr., van Belle, G., Daling, J.R., and McKnight, B. (1994). Aspartame ingestion and headaches: a randomized crossover trial. Neurology 44, 1787-1793. (Pubitemid 24319196)
38. Walter, M. (2009). Interrelationships among HDL metabolism, aging, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29, 1244-1250.
39. Weihrauch, M.R., and Diehl, V. (2004). Artificial sweeteners-do they bear a carcinogenic risk? Ann. Oncol. 15, 1460-1465. (Pubitemid 39409734)
40. Zeng, R.Z., Kim, H.G., Kim, N.R., Lee, H.Y., Jung, B.J., Ko, M.Y., Lee, S.Y., and Chung, D.K. (2010). Protein expression changes in human monocytic THP-1 cells treated with lipoteichoic acid from Lactobacillus plantarum and Staphylococcus aureus. Mol. Cells 29, 585-594